These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20479027)

  • 1. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.
    Ito K; Elkin EB; Girotra M; Morris MJ
    Ann Intern Med; 2010 May; 152(10):621-9. PubMed ID: 20479027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
    Moriwaki K; Fukuda H
    Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
    Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
    J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
    Schousboe JT; Taylor BC; Fink HA; Kane RL; Cummings SR; Orwoll ES; Melton LJ; Bauer DC; Ensrud KE
    JAMA; 2007 Aug; 298(6):629-37. PubMed ID: 17684185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
    Yoshizawa T; Nishino T; Okubo I; Yamazaki M
    Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
    Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
    Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
    Kiratli BJ; Srinivas S; Perkash I; Terris MK
    Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX.
    Adler RA; Hastings FW; Petkov VI
    Osteoporos Int; 2010 Apr; 21(4):647-53. PubMed ID: 19533207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy.
    James H; Aleksic I; Bienz MN; Pieczonka C; Iannotta P; Albala D; Mariados N; Mouraviev V; Saad F
    Urology; 2014 Jul; 84(1):164-8. PubMed ID: 24976229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
    Bayoumi AM; Brown AD; Garber AM
    J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
    Kreck S; Klaus J; Leidl R; von Tirpitz C; Konnopka A; Matschinger H; König HH
    Pharmacoeconomics; 2008; 26(4):311-28. PubMed ID: 18370566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.
    Bruder JM; Ma JZ; Wing N; Basler J; Katselnik D
    J Clin Densitom; 2006; 9(4):431-7. PubMed ID: 17097529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.
    Borgström F; Johnell O; Jönsson B; Zethraeus N; Sen SS
    Bone; 2004 Jun; 34(6):1064-71. PubMed ID: 15193554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.